Highlighted Study: SARS-CoV-2 Serology Status Detected by Commercialized Platforms Distinguishes Previous Infection and Vaccination Adaptive Immune Responses

SAN DIEGO, CA ? (March 15, 2021) In a newly published (preprint) study, UCSD and Scripps research group uses Diazyme developed technology for high throughput COVID-19 neutralizing antibody detection. The research study showed strong correlation of the Diazyme technology to PSV SARS-CoV-2 Neutralizing antibody test.

Click below to read the full (preprint) study:

SARS-CoV-2 Serology Status Detected by Commercialized Platforms Distinguishes Previous Infection and Vaccination Adaptive Immune Responses